Search academic texts

Information × Registration Number 0220U100542, 0117U001047 , R & D reports Title Defining the role of molecular biomarkers in assessing the aggressiveness of uterine sarcoma popup.stage_title Head Simonova-Pyshkar Larisa I., д.мед.н.Sukhina Olena M., Доктор медичних наук Registration Date 21-01-2020 Organization State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine" popup.description2  Object of study: combined treatment of uterine sarcomas, molecular and biological characteristics of the tumor. Objective: to increase the efficiency of diagnostics, treatment and prognosis of uterine sarcoma through the determination of the role of some molecular biological characteristics of aggressiveness of uterine sarcoma for the individualization of therapy. Methods and apparatus: roentgenological, morphological, clinical, instrumental, statistical; universal dosimeter UNIDOS-E, ultrasound diagnostic system VOLUSON E8 Expert. Theoretical and practical results: The effect of Bcl 2 expression, progesterone and estrogen positive coexpression on the tumor progression rate has been theoretically substantiated 2.5, 1.9 and 2.8 times, respectively. It is substantiated that individualized antiblastoma therapy of uterine sarcoma reduces the recurrence rate by 2 times, increases the 5-year survival rate by 14.0–20.0%, respectively, in stages I and II. Methods of radiotherapy of uterine sarcoma and stage of use of which allows to increase the effectiveness of therapy have been developed. A method of differential diagnosis of leiomyoma and uterine leiomyosarcoma has been developed, which allows to choose individual tactics of surgery. Novelty: New data on peculiarities of metastasis and recurrence of uterine sarcoma depending on the level of molecular-biological markers are obtained, and a complex of measures of diagnostic, therapeutic and prognostic orientation for individualization of therapy taking into account aggression of uterine sarcoma is substantiated. The effectiveness of implementation: the absence of adjuvant CTx during six hospitalizations allows saving about 15 thousand UAH for one patient. Field of use: oncology, radiology. Product Description popup.authors Artamonova Neonila O. Hertman Vira Z. Hranovska Hanna I. Dolhaia Oksana V. Zadniprovska Nataliia Oleksandrivna Kolomatska Viktoriia V. Kruhova Iryna M. Lysenko Viktoriia M. Liakhovska Nataliia V. Nasonova Alla M. Nemaltsova Kateryna V. Radchenko Oleksandr A. Simonova-Pushkar Larysa I. Spliukhyna Olha V. Sukhin Vladyslav S. Sukhina Olena M. Fedorenko Kateryna S. Shustov Ihor B. Yakovenko Kyrylо V. popup.nrat_date 2020-04-02 Close